Vascular and haematopoietic stem cells: Novel targets for anti-angiogenesis therapy?

Nature Reviews Cancer

Volumn 2, Issue 11, 2002, Pages 826-835

  Rafii, Shahin ^a   Lyden, David ^a,b   Benezra, Robert ^a,b   Hattori, Koichi ^a   Heissig, Beate ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PLATELET DERIVED GROWTH FACTOR; STEM CELL FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN INHIBITOR; ANGIOGENESIS INHIBITOR; ENDOTHELIAL CELL GROWTH FACTOR; GELATINASE B; LYMPHOKINE; SIGNAL PEPTIDE; TUMOR PROTEIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; BONE MARROW TOXICITY; CELL MIGRATION; DRUG TARGETING; ENDOTHELIUM CELL; HEMATOPOIETIC STEM CELL; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; STEM CELL; TUMOR VASCULARIZATION; ANIMAL; BLOOD VESSEL; BONE MARROW CELL; CELL DIFFERENTIATION; CELL LINEAGE; CELL MOTION; DRUG EFFECT; EXPERIMENTAL NEOPLASM; FORECASTING; MOUSE; MOUSE MUTANT; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHYSIOLOGY; VASCULAR ENDOTHELIUM; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; BLOOD VESSELS; BONE MARROW CELLS; CELL DIFFERENTIATION; CELL LINEAGE; CELL MOVEMENT; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM, VASCULAR; FORECASTING; HEMATOPOIETIC STEM CELLS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOKINES; MATRIX METALLOPROTEINASE 9; MICE; MICE, KNOCKOUT; NEOPLASM PROTEINS; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; STEM CELLS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0036831559     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc925     Document Type: Review

References (103)

1. Hanahan, D. & Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86, 353-364 (1996).
2. Folkman, J., Watson, K., Ingber D. & Hanahan, D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339, 58-61 (1989).
3. Tlsty, T. D. Stromal cells can contribute oncogenic signals. Semin. Cancer Biol. 11, 97-104 (2001).
4. Carmeliet, P. & Jain, R. K. Angiogenesis in cancer and other diseases. Nature 407, 249-257 (2000).
5. Yancopoulos, G. D. et al. Vascular-specific growth factors and blood vessel formation. Nature 407, 242-248 (2000).
6. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med. 1, 27-31 (1995).
7. Lyden, D. et al. Impaired recruitment of bone-marrow-derived endothelial and haematopoietic precursor cells blocks tumor angiogenesis and growth. Nature Med. 7, 1194-1201 (2001). Demonstrates the significance of mobilization and incorporation of circulating endothelial precursor and haematopoietic cells in supporting tumour angiogenesis. Transplantation and engraftment of wild-type bone marrow into tumour-resistant Id-mutant mice results in the restoration of tumour angiogenesis and growth.
8. + multipotential adult progenitor (MAPC) cells injected into immunocompromised mice have the potential to contribute to tumour angiogenesis of xenotransplanted, as well as spontaneous, tumours.
9. Moore, M. A. Putting the neo into neoangiogenesis. J. Clin. Invest. 109, 313-315 (2002).
10. Asahara, T. et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ. Res. 85, 221-228 (1999).
11. Gehling, U. M. et al. In vitro differentiation of endothelial cells from AC133-positive progenitor cells. Blood 95, 3106-3112 (2000).
12. Marchetti, S. et al. Endothelial cells genetically selected from differentiating mouse embryonic stem cells incorporate at sites of neovascularization in vivo. J. Cell Sci. 115, 2075-2085 (2002).
13. Davidoff, A. M. Bone marrow-derived cells contribute to tumor neovasculature and, when modified to express an angiogenesis inhibitor, can restrict tumor growth in mice. Clin. Cancer Res. 7, 2870-2879 (2001).
14. Ito, H. et al. Endothelial progenitor cells as putative targets for angiostatin Cancer Res. 59, 5875-5877 (1999).
15. + cells exert a cytotoxic bystander effect on human endothelial and cancer cells. Clin. Cancer Res. 6, 4442-4448 (2000).
16. Carmeliet, P. & Luttun, A. The emerging role of the bone marrow-derived stem cells in (therapeutic) angiogenesis. Thromb. Haemost. 86, 289-297 (2001).
17. Dvorak, H. F., Nagy, J. A., Dvorak, J. T. & Dvorak, A. M. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am. J. Pathol. 133, 95-109 (1988).
18. Monkawa, S. et al. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am. J. Pathol. 160, 985-1000 (2002).
19. Bergers, G., Javaherian, K., Lo, K. M., Folkman, J. & Hanahan, D. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284, 808-812 (1999).
20. Holash, J. et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284, 1994-1998 (1999). Shows the role of vessel co-option in supporting tumour angiogenesis. The TIE2/angiopoietin signalling pathway is involved in the remodelling during co-option process.
21. Leung, D. W., Cachianes, G., Kuang, W. J., Goeddel, D. V. & Ferrara, N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246, 1306-1309 (1989).
22. Kim, K. J. et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362, 841-844 (1993).
23. Shalaby, F. et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376, 62-66 (1995).
24. Terman, B. I. et al. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem. Biophys. Res. Commun. 187, 1579-1586 (1992).
25. Neufeld, G., Cohen, T., Gengrinovitch, S. & Poltorak, Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 13, 9-22 (1999).
26. Millauer, B., Shawver, L. K., Plate, K. H., Risau, W. & Ullrich, A. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 367, 576-579 (1994).
27. Pepper, M. S. & Mandriota, S. J. Regulation of vascular endothelial growth factor receptor-2 (Flk-1) expression in vascular endothelial cells. Exp. Cell Res. 241, 414-425 (1998).
28. Fong, G. H., Rossant, J., Gertsenstefn, M. & Breitman, M. L. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376, 66-70 (1995).
29. Hiratsuka, S. et al. Involvement of Flt-1 tyrosine kinase (vascular endothelial growth factor receptor-1) in pathological angiogenesis. Cancer Res. 61, 1207-1213 (2001).
30. Benjamin, L. E. & Keshet, E. Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc. Natl Acad. Sci. USA 94, 8761-8766 (1997).
31. Benjamin, L. E., Golijanin, D., Itin, A., Pode, D. & Keshet, E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J. Clin. Invest. 103, 159-165 (1999).
32. Mandriota, S. J. et al. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J. 20, 672-682 (2001).
33. Skobe, M. et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nature Med. 7, 192-198 (2001).
34. Makinen, T. et al. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nature Med. 7, 199-205 (2001).
35. Folberg, R., Hendrix, M. J. & Maniotis, A. J. Vasculogenic mimicry and tumor angiogenesis. Am. J. Pathol. 156, 361-381 (2000).
36. Hendrix, M. J. et al. Expression and functional significance of VE-cadherin in aggressive human melanoma cells: role in vasculogenic mimicry. Proc. Natl Acad. Sci. USA 98, 8018-8023 (2001).
37. Chang, Y. S. et al. Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc. Natl Acad. Sci. USA 97, 14606-14613 (2000).
38. Folkman, J. Can mosaic tumor vessels facilitate molecular diagnosis of cancer? Proc. Natl Acad. Sci. USA 98, 398-400 (2001).
39. Lyden, D. et al. Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts. Nature 401, 670-677 (1999). Reports that Id-mutant mice fail to support the growth of xenotransplanted tumours. The mechanism for tumour resistance in Id-mutant mice is mainly due to defects in tumour angiogenesis.
40. Segal, M. S., Bihorac, A. & Koc, M. Circulating endothelial cells: tea leaves for renal disease. Am. J. Physiol. Renal Physiol. 283, F11-F19 (2002).
41. Mutunga, M. et al. Circulating endothelial cells in patients with septic shock. Am. J. Respir. Crit. Care Med. 163, 196-200 (2001).
42. George, F. et al. Demonstration of Rickettsia conorii-induced endothelial injury in vivo by measuring circulating endothelial cells, thrombomodulin, and von Willebrand factor in patients with Mediterranean spotted fever. Blood 82, 2109-2116 (1993).
43. Lefevre, P., George, F., Durand, J. M. & Sampol, J. Detection of circulating endothelial cells in thrombotic thrombocytopenic purpura. Thromb. Haemost. 69, 522 (1993).
44. Shi, Q. et al. Proof of fallout endothelialization of impervious Dacron grafts in the aorta and inferior vena cava of the dog. J. Vasc. Surg. 20, 546-556 (1994).
45. Solovey, A. et al. Circulating activated endothelial cells in sickle cell anemia. N. Engl. J. Med. 337, 1584-1590 (1997).
46. Asahara, T. et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 275, 964-967 (1997). Shows that bone-marrow-derived endothelial progenitors can contribute to post-natal angiogenic processes, including hind-limb ischaemia.
47. Shi, Q. et al. Evidence for circulating bone marrow-derived endothelial cells. Blood 92, 362-367 (1998). Shows that bone-marrow-derived cells can contribute to the endothelialization of the Dacron grafts. Most of the endothelial cells on the surface of the implanted Dacron grafts originated from the transplanted donor bone-marow-derived endothelial cells.
48. Lin, Y., Weisdorf, D. J., Solovey A. & Hebbel, R. P. Origins of circulating endothelial cells and endothelial outgrowth from blood. J. Clin. Invest. 105, 71-77 (2000). Shows the potential of bone-marrow-derived circulating endothelial precursor cells to generate late outgrowth highly proliferative endothelial monolayers. By contrast, circulating endothelial cells and vascular-wall-derived endothelial cells gave rise to early outgrowth endothelial cells with limited proliferative potential.
49. Rafii, S. Circulating endothelial precursors: mystery, reality, and promise. J. Clin. Invest. 105, 17-19 (2000).
50. Takahashi, T. et al. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nature Med. 5, 434-438 (1999).
51. Rafii, S. et al. Characterization of haematopoietic cells arising on the textured surface of left ventricular assist devices. Ann. Thorac. Surg. 60, 1627-1632 (1995).
52. Gill, M. et al. Vascular trauma induces rapid but transient mobilization of VEGFR2(+)AC133(+) endothelial precursor cells. Circ. Res. 88, 167-174 (2001).
53. Peichev, M. et al. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood 95, 962-968 (2000). This report in conjunction with references 11 and 54, shows that CD133 is expressed on the circulating endothelial precursor cells, and its expression diminishes after differentiation to adherent mature endothelial cells.
54. Quirici, N. et al. Differentiation and expansion of endothelial cells from human bone marrow CD133(+) cells. Br. J. Haematol. 115, 186-194 (2001).
55. Miraglia, S. et al. A novel five-transmembrane haematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood 90, 5013-5021 (1997).
56. Yin, A. H. et al. AC133, a novel marker for human haematopoietic stem and progenitor cells. Blood 90, 5002-5012 (1997).
57. Miraglia, S., Godfrey, W. & Buck, D. A response to AC133 haematopoietic stem cell antigen: human homologue of mouse kidney prominin or distinct member of a novel protein family? Blood 91, 4390-4391 (1998).
58. Coffin, J. D., Harrison, J., Schwartz, S. & Heimark, R. Angioblast differentiation and morphogenesis of the vascular endothelium in the mouse embryo. Dev. Biol. 148, 51-62 (1991).
59. Robert, B., St John, P. L., Hyink, D. P. & Abrahamson, D. R. Evidence that embryonic kidney cells expressing flk-1 are intrinsic, vasculogenic angioblasts. Am. J. Physiol. 271, F744-F753 (1996).
60. Caprioli, A., Jaffredo, T., Gautier, R., Dubourg, C. & Dieterlen-Lievre, F. Blood-borne seeding by haematopoietic and endothelial precursors from the allantois. Proc. Natl Acad. Sci. USA 95, 1641-1646 (1998).
61. Mancuso, P. et al. Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood 97, 3658-3661 (2001).
62. Monestiroli, S. et al. Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma. Cancer Res. 61, 4341-4344 (2001).
63. Cameliet, P. et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nature Med. 7, 575-583 (2001).
64. Luttun, A. et al. Revascularization of ischemic tissues by PIGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nature Med. 1, 1 (2002).
65. Polverini, P. J. & Leibovich, S. J. Induction of neovascularization in vivo and endothelial proliferation in vitro by tumor-associated macrophages. Lab. Invest. 51, 635-642 (1984).
66. Polverini, P. J., Cotran, P. S., Gimbrone, M. A. Jr & Unanue, E. R. Activated macrophages induce vascular proliferation. Nature 269, 804-806 (1977).
67. Dahlqvist, K., Umemoto, E. Y., Brokaw, J. J., Dupuis, M. & McDonald, D. M. Tissue macrophages associated with angiogenesis in chronic airway inflammation in rats. Am. J. Respir. Cell. Mol. Biol. 20, 237-247 (1999).
68. Ezaki, T. et al. Time course of endothelial cell proliferation and microvascular remodeling in chronic inflammation. Am. J. Pathol. 158, 2043-2055 (2001).
69. McDonald, D. M. Angiogenesis and remodeling of airway vasculature in chronic inflammation. Am. J. Respir. Crit. Care Med. 164, S39-S45 (2001).
70. Leibovich, S. J. et al. Macrophage-induced angiogenesis is mediated by tumour necrosis factor-alpha. Nature 329, 630-632 (1987).
71. Di Pietro, L. A. & Polverini, P. J. Angiogenic macrophages produce the angiogenic inhibitor thrombospondin 1. Am. J. Pathol. 143, 678-684 (1993).
72. Coussens, L. M., Tinkle, C. L., Hanahan, D. & Werb, Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 103, 481-490 (2000). Shows the essential role of tumour-associated macrophages in supporting tumour growth. MMP-9 that is supplied by tumour-inflitrating macrophages restores impaired tumour growth in Mmp-9-deficient mice. This indicates that MMP-9, provided by bone-marrow-derived cells, is necessary for tumour growth.
73. Takakura, N. et al. A role for haematopoietic stem cells in promoting angiogenesis. Cell 102, 199-209 (2000).
74. Donovan, M. J. et al. Brain derived neurotrophic factor is an endothelial cell survival factor required for intramyocardial vessel stabilization. Development 127, 4531-4540 (2000).
75. Skobe, M. et al. Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma. Am. J. Pathol. 159, 893-903 (2001).
76. Kadambi, A. et al. Vascular endothelial growth factor (VEGF)-C differentially affects tumor vascular function and leukocyte recruitment: role of VEGF-receptor 2 and host VEGF-A. Cancer Res. 61, 2404-2408 (2001).
77. Reya, T., Morrison, S. J., Clarke, M. F. & Weissman, I. L. Stem cells, cancer, and cancer stem cells. Nature 414, 105-111 (2001).
78. Krause, D. S. et al. Multi-organ, multi-lineage engraftment by a single bone marrow-derived stem cell. Cell 105, 369-377 (2001).
79. Blau, H. M., Brazelton, T. R. & Weimann, J. M. The evolving concept of a stem cell: entity or function? Cell 105, 829-841 (2001).
80. Cheng, T. et al. Haematopoietic stem cell quiescence maintained by p21Cip1/Waf1. Science 287, 1804-1808 (2000).
81. Vu, T. H. & Werb, Z. Matrix metalloproteinases: effectors of development and normal physiology. Genes Dev. 14, 2123-2133 (2000).
82. Bergers, G. et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nature Cell Biol. 2, 737-744 (2000).
83. Engsig, M. T. et al. Matrix metalloproteinase 9 and vascular endothelial growth factor are essential for osteoclast recruitment into developing long bones. J. Cell Biol. 151, 879-890 (2000).
84. Heissig, B. et al. Recruitment of stem and progenitor cells from the bone marrow niche requires Mmp-9 mediated release of Kit-ligand. Cell 109, 625-637 (2002). Shows the mechanism by which bone-marrow-derived stem and progenitor cells are recruited from the bone-marrow microenvironment to the peripheral circulation. Physiological stressors, including bone-marrow suppression or elevation of angiogenic factors, induce MMP-9, resulting in the release of soluble KIT ligand, driving the proliferation and mobilization of stem and progenitor cells.
85. Hattori, K. et al. Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and haematopoietic stem cells. J. Exp. Med. 193, 1005-1014 (2001).
86. Ziegler, B. L. et al. KDR receptor: a key marker defining haematopoietic stem cells. Science 285, 1553-1558 (1999).
87. Sawano, A. et al. Flt-1, vascular endothelial growth factor receptor 1, is a novel cell surface marker for the lineage of monocyte-macrophages in humans. Blood 97, 785-791 (2001).
88. Clauss, M. et al. The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. J. Biol. Chem. 271, 17629-17634 (1996).
89. Badeon, B. et al. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 87, 3336-3343 (1996).
90. Cho, N. K. et al. Developmental control of blood cell migration by the Drosophila VEGF pathway. Cell 108, 865-876 (2002).
91. Hattori, K. et al. Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment. Nature Med. 1, 1 (2002). Defines the mechanism by which angiogenic factors, including placental-derived growth factor (PIGF) and vascular endothelial growth factor (VEGF), recruit haematopoietic cells from bone marrow to the tumour vasculature. VEGFR1 is expressed on haematopoietic stem and progenitor cells and conveys signals that promote motility and MMP-9-mediated release of sKitL, thereby directing mobilization of these cells to the peripheral circulation.
92. Gerber, H. P. et al. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 417, 954-958 (2002). Shows the expression of VEGF receptors, including VEGFR1, on the haematopoietic stem cells, conveying signals that support proliferation and survival of these cells through a novel intrakine signalling mechanism.
93. Eriksson, U. & Alitalo, K. VEGF receptor 1 stimulates stem-cell recruitment and new hope for angiogenesis therapies. Nature Med. 8. 775-777 (2002).
94. Dias, S. et al. Inhibition of both paracrine and autocrine VEGF/VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias. Proc. Natl Acad. Sci. USA 98, 10857-10862 (2001).
95. Dias, S. et al. Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J. Clin. Invest. 106, 511-521 (2000).
96. + cells as cellular vehicles for gene delivery into areas of angiogenesis in a rhesus model. Gene Ther. 7, 43-52 (2000).
97. Levenberg, S., Golub, J. S., Amit, M., Itskovitz-Eldor, J. & Langer, R. Endothelial cells derived from human embryonic stem cells. Proc. Natl Acad. Sci. USA 99, 4391-4396 (2002).
98. Vittet, D. et al. Embryonic stem cells differentiate in vitro to endothelial cells through successive maturation steps. Blood 88, 3424-3431 (1996).
99. Kabrun, N. et al. Flk-1 expression defines a population of early embryonic haematopoietic precursors. Development 124, 2039-2048 (1997).
100. Choi, K., Kennedy, M., Kazarov, A., Papadimitriou, J. C. & Keller, G. A common precursor for haematopoietic and endothelial cells. Development 125, 725-732 (1998).
101. Hirashima, M., Kataoka, H., Nishikawa, S., Matsuyoshi, N. & Nishikawa, S. Maturation of embryonic stem cells into endothelial cells in an in vitro model of vasculogenesis. Blood 93, 1253-1263 (1999).
102. Yamashita, J. et al. Flk1-positive cells derived from embryonic stem cells serve as vascular progenitors. Nature 408, 92-96 (2000).
103. Wijelath, E. S. et al. Novel vascular endothelial growth factor binding domains of fibronectin enhance vascular endothelial growth factor biological activity. Circ. Res. 91, 25-31 (2002). Demonstrates the capacity of fibronectin to bind to VEGF, Co-engagment of VEGFA/fibronectin with the VEGFR2/integrin complex that is expressed on endothelial cells can potentiate VEGF signalling.